Get Premium

User

Get Premium

Dominate Financial Markets with Stock Target Advisor Premium Features

Analyst Ratings
Analyst Ratings

Daily targets and ratings from professional analysts
- LATEST ANALYST RATINGS
- Latest Analyst Ratings
- Top Analysts Screener
- Analyst Directory
- My Analysts
- LATEST RATINGS BY COUNTRY
- Canada
- USA
- UK
- India
- France
- Germany
Best Stocks
Best Stocks

Quickly zoom in on the stocks with highest and lowest potential based on analyst recommendations and Stock Target Advisor's own analysis
- Automatic Selection
- Top Stocks
- Worst Stocks
- Best Penny Stocks
- Best Performing Stocks
- Worst Performing Stocks
- BEST STOCKS FILTERS
- All Countries
- Canada
- USA
- UK
- India
- France
- Germany
Smart Screens
Smart Screens

Search stocks using 100s of variables and make your own screens
- Search
- Stock Screener
- Advanced Stock Search
- Industries
- Prebuilt Screens
- Popular Screens
- Cryptocurrency Stocks
- Canadian SPACs
- US SPACs
- High Dividend Stocks
- Low Cost Global Equity ETFs
- Reputable Companies
Watchlists & Portfolios
Watchlists & Portfolios

Track and analyze your holdings and favorite stocks
- My Watchlists
- My Portfolios
News & Calendars
News & Calendars

Stay on top of what’s happening in all markets
Insights
Insights

Latest research and insights from our analysts and users
Crowd Ratings
Crowd Ratings

Targets and analysis from users like you
Pricing
About Us

Search Blog

Contribute to our Blog

Tag: AMGN stocktwits

Amgen’s $27.8 Billion Deal for Horizon Therapeutics Faces FTC Hurdle

Piper Jaffray Co. lowers the target on Amgen Inc. (AMGN:NSD) on low Q1 profits

Get our Premium Service free for 7-days!

Link watchlist to your brokerage
Premium Newsletter
Daily Analyst Ratings
Detailed Stock Analysis
Top Picks
Watchlists and Portfolios
Advanced Screens
Detailed Reports
Donwloadable Data

Join over half-million smart investors across the world

Select Market

I agree to Stock Target Adivsor Terms and Conditions

or Sign up with